Collaborative Practice Agreements

Kayla Wallentine, 2019 PharmD Candidate, Idaho State University College of Pharmacy

Through collaborative practice agreements, the Nevada Legislature expanded the scope of services that Nevada-registered pharmacists can provide to patients, including as part of an interdisciplinary team. The requirements of a valid collaborative practice agreement are found in Nevada Revised Statutes (NRS) 639.2623 and NRS 639.2627, which allow pharmacists to engage in the collaborative practice of pharmacy and in collaborative drug therapy management, pursuant to a collaborative practice agreement.

A collaborative practice agreement is a written agreement made between one or more practitioners and pharmacists that authorizes a pharmacist to perform tests to address chronic disease states or public health issues. Through a collaborative practice agreement, a pharmacist may engage in the collaborative practice of pharmacy, as defined in NRS 639.00525, or in collaborative drug therapy management, as defined in NRS 639.0051, where a pharmacist may initiate, monitor, modify, or discontinue patients’ drug therapies.

To enter into a valid collaborative practice agreement, a practitioner must be licensed and in good standing in the state of Nevada. The practitioner must also maintain an ongoing relationship with the patient, who must give informed, written consent before the pharmacist may provide services to that patient pursuant to the collaborative practice agreement.

Additionally, the collaborative practice agreement must specify the disease state(s) a pharmacist may help treat, the types of decisions a pharmacist may make, and the procedure(s) a pharmacist may carry out, pursuant to the collaborative practice agreement. The agreement must also include a description as to how a practitioner will communicate any necessary medical information and diagnosis to the pharmacist and monitor clinical outcomes. Further, the agreement must state that the practitioner is authorized to override the agreement to protect the patient and accomplish treatment goals. The pharmacist must also comply with the requirements documented in the collaborative practice agreement concerning how a pharmacist must document, maintain records, and communicate with the practitioner and patients regarding patient care, treatment, and adverse effects, per NRS 639.2623 Section 3(a), (b), and (c); NRS 639.2627 Section 1(a), (b), and (c). Of note, NRS 639.2623 Section 5 states, “A practitioner may not enter into a collaborative practice agreement with a pharmacist for the management of controlled substances.”

Further, collaborative practice agreements are only effective for up to one year after the effective date. To renew the agreement, all parties must review it, make any necessary changes, and sign an updated agreement. These agreements must be submitted to the Nevada State Board of Pharmacy for approval in both a written and electronic form before they are effective.

Finally, Registered Pharmacists Can Collect Specimens!

Prior to July 1, 2017, registered pharmacists were not allowed to manipulate a patient to collect a specimen for laboratory testing. Do not let that deter you now that this

continued on page 4
FDA Launches Pilot Program to Improve Security of Drug Supply Chain With an Innovative Approach

Food and Drug Administration (FDA) has launched a pilot program allowing participants representing the various parts of the drug supply chain to pilot innovative and emerging approaches for enhanced tracing and verification of prescription drugs in the United States’ supply chain. The program is in line with FDA’s ongoing efforts to prevent suspect and illegitimate products from entering the supply chain, according to an FDA press release. Eligible manufacturers, repackers, and other stakeholders can apply to participate in the program, which will inform the development of the enhanced electronic, interoperable track-and-trace system for industry set to go into effect in 2023 in accordance with the Drug Supply Chain Security Act (DSCSA), enacted by Congress on November 27, 2013.

The pilot technologies of this program may become part of FDA’s enhanced expectations for reliable track-and-trace systems, which will be designed to reduce diversion of drugs distributed domestically and to keep counterfeit drugs from entering the supply chain. The DSCSA pilot project program is intended to help identify and evaluate the most efficient processes to comply with and apply drug supply chain security requirements and will aid in identifying attributes the system will need for enhanced product tracing and verification, as well as electronic means to share the information. FDA recently issued draft guidance on the use of product identifiers with a unique serial number to improve verification down to the package level. FDA has also provided draft guidance for verification systems to quarantine and investigate suspect and illegitimate drugs.

Additional information on the FDA pilot program is available in a February 8, 2019 announcement in the Federal Register.

FDA Announces New Efforts to Increase Oversight and Strengthen Regulation of Dietary Supplements

Noting that three in four Americans now take at least one dietary supplement on a regular basis, and that the dietary supplement industry has expanded to include as many as 80,000 different products for consumers, FDA Commissioner Scott Gottlieb, MD, has announced new plans to increase the agency’s oversight of dietary supplements.

These initiatives include communicating to the public as soon as possible when there is a concern about a dietary supplement on the market, ensuring that the regulatory framework is flexible enough to adequately evaluate product safety, and continuing to work closely with industry partners. FDA is also developing new enforcement strategies to respond to entities that violate standards established under the Dietary Supplement Health and Education Act of 1994.

On February 11, 2019, FDA sent 12 warning letters and five online advisory letters to foreign and domestic companies that are illegally selling more than 58 products. The products are illegally marketed as unapproved new drugs that make unproven claims about preventing, treating, or curing Alzheimer’s disease, as well as a number of other serious diseases and health conditions, such as diabetes and cancer. In his statement, Gottlieb noted that most stakeholders in the industry act responsibly, but he expressed concern over the ability of bad actors to exploit the system by providing potentially dangerous products and making unproven or misleading claims about the health benefits supplements may offer.

FDA is planning a public meeting on this topic during the second quarter of 2019. For more information, view the FDA statement at https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm631065.htm.

Trump Administration Releases National Drug Control Strategy to Reduce Drug Trafficking and Abuse

As the opioid crisis continues to claim the lives of tens of thousands of Americans each year, the Office of National Drug Control Policy has released its National Drug Control Strategy. The Strategy breaks down the administration’s priorities in addressing the crisis, with an emphasis on three areas: prevention, treatment and recovery, and reducing availability.

♦ Prevention efforts are focused on educating both consumers and caregivers about the dangers of opioid misuse and include a new national media campaign, continued efforts to expand prescription monitoring programs (PMPs), and improving the ability of state, local, and tribal communities to identify and prevent substance abuse.

♦ Treatment and recovery recommendations in the Strategy include improving access to naloxone, improving evidence-based addiction treatment, and eliminating barriers for accessing treatment.
Reducing availability strategies are focused on disrupting illegal supply chains, defeating drug traffickers, increased cooperation with international partners, and combating illegal internet drug sales.

The document notes that the “most important criterion of success” is saving lives and calls for the federal government to work closely with state and local governments, as well as other stakeholders. Additional information, including the full strategy document, is available on the White House website at https://www.whitehouse.gov/opioids.

National Association of Boards of Pharmacy® (NABP®) and its member boards of pharmacy remain committed to advancing best practices for PMPs in the interest of public health. NABP’s PMP data sharing system, NABP PMP InterConnect®, facilitates the secure transfer of PMP data across state lines and provides an effective means of combating drug diversion and drug abuse nationwide. In addition, NABP and its member boards continue efforts to educate consumers about prescription drug safety. The NABP AWARXE® Prescription Drug Safety Program’s Drug Disposal Locator Tool has more than 6,000 disposal locations and continues to add new locations to provide consumers with a safe way to dispose of medication and help prevent misuse and abuse of prescription medications. For more information about PMP InterConnect and the AWARXE program, visit the Initiatives section of the NABP website at www.nabp.pharmacy.

New Study Predicts Opioid Epidemic Will Worsen Over the Next Decade

More than 700,000 people will die from opioid overdoses between 2016 and 2025, and annual overdose deaths will reach nearly 82,000 by 2025, estimates a new study published to JAMA Network Open. The estimate is based on an analysis of data from the National Survey on Drug Use and Health and the Centers for Disease Control and Prevention from 2002 to 2015.

Researchers also projected that intervention efforts focused on lowering the incidence of prescription opioid misuse would help to reduce the number of deaths 3.8% to 5.3%, a figure the researchers described as “modest,” due to the changing nature of the opioid crisis. The study notes that more people are directly initiating opioid use with illicit opioids rather than prescription drugs, and illicit opioids have become more lethal with the availability of illegally manufactured fentanyl.

The researchers encourage policymakers to take “a stronger and multipronged approach” to reduce the impact of the ongoing opioid overdose epidemic. The full article is available at https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2723405.

FDA Warns of Potential Blood Pressure Medication Shortages Due to Recalls

FDA is warning health care providers and consumers of a shortage of angiotensin II receptor blockers, commonly used to treat high blood pressure. A growing list of medications containing valsartan, losartan, and irbesartan have been recalled from the market for containing an impurity that may present a cancer risk to patients. The issue was first detected in the summer of 2018, according to a statement posted to the FDA website. Since then, FDA has placed a Chinese manufacturer of the active ingredient on import alert to stop their imports, and FDA is working with other manufacturers to recall affected medications.

In the statement, FDA notes that the risk to individual patients remains very small, but that there is still reason to be concerned about the potential health risks. Medications with these impurities are believed to have been in the market for about four years.

“Now that these risks are identified, we’re applying what we’ve learned to the evaluation of similar manufacturing processes where we now know these risks could arise,” the statement notes. The FDA press release is available at https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm629796.htm.

FDA Releases Two Draft Guidances Related to REMS Programs

FDA has released two new draft guidances to ensure risk mitigation programs put in place for certain drugs and biologics, as required for approval, are working. The agency’s primary risk management tool is FDA-approved product labeling. However, in limited cases, FDA may require a Risk Evaluation and Mitigation Strategy (REMS) to help ensure a drug’s benefits outweigh its risks.

The following guidances relate to the assessment of REMS programs:

♦ REMS Assessment: Planning and Reporting Guidance for Industry describes how to develop a REMS Assessment Plan.
♦ Survey Methodologies to Assess REMS Goals That Relate to Knowledge Guidance for Industry provides recommendations on conducting REMS assessment surveys to evaluate patient or health care provider knowledge of REMS-related information. FDA states that the goal in providing this guidance for REMS is to ensure constant improvement of their safety programs and establish the most efficient and effective programs moving forward, to optimize patient care and keep consumers safe and healthy. More information on REMS is available on the FDA website at https://www.fda.gov/drugs/drugsafety/remS.
practice is allowed! Collecting specimens is not as bad as you might think. A registered pharmacist may use a fingerstick or an oral or nasal swab to perform Clinical Laboratory Improvement Amendments-waived tests per NRS 639.0747 and NRS 652.210. For example, a registered pharmacist can now perform tests for blood glucose levels, the international normalized ratio, influenza, and strep throat. Registered pharmacists are still not allowed to collect urine or stool specimens.

**Disclaimer:** This information is provided as a courtesy on behalf of the Nevada State Board of Pharmacy. This information does not constitute legal advice and does not override the specific provisions of Nevada law as applied to a particular set of facts.